WIREDUP: Wearable Insoles for Recurrent Diabetic Ulcer Prevention

NCT05950659 | Not Yet Recruiting DMC

• 1 other identifier: WIREDUP
• Study Type: interventional
• Target: 400
• Locations: 0 countries
• Sites: N/A

Brief Summary

The primary aim of this study is to demonstrate the impact of the Orpyx® Sensory Insoles (Orpyx Medical Technologies Inc., Calgary AB, Canada) ("Orpyx" or "the Company") as an adjunct to the standard of care (SOC), as compared to SOC alone, on reducing plantar ulceration incidence in individuals who are at risk for developing diabetic foot complications. The secondary aims of this study are to evaluate participant quality of life, participant engagement, and economic impact, including cost-effectiveness and cost-utility. The study will also use the unique data set collected (plantar pressure, temperature, step count, movement and adherence feedback) to identify foot-loading histories that either lead to or prevent the development of ulceration in the diabetic foot.

Conditions

Diabetes; Peripheral Neuropathy; Diabetic Foot; Diabetic Foot Ulcer

Keywords

Remote Patient Monitoring; Sensor-based Monitoring; Sensory Insoles

Outcome Measures

Primary Outcomes (1)

• Plantar ulcer recurrence

  12 months

Study Arms (2)

Intervention

EXPERIMENTAL

Device: Orpyx Sensory Insole System

Control

NO INTERVENTION

Interventions

Orpyx Sensory Insole System DEVICE

The Orpyx Sensory Insoles System uses Orpyx Sensory Technology: a powered limb overload warning technology intended for monitoring physiologic parameters, such as plantar pressure, temperature, motion, and adherence, and providing real-time cues for pressure offloading

Intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosed Type 1 or 2 diabetes
• Clinically diagnosed neuropathy via Neuropathy Monofilament Test
• Qualification as a "high-risk participant," meaning a recent history (\<12 months) of a healed diabetic neuropathic ulceration on the weight-bearing surface of one or both feet (this includes the plantar distal toe surface)
• Complete healing of any previous foot ulcers, as defined by complete re-epithelialization of that ulcer which is confirmed by two medical exams that occur at least two weeks apart (V0 and V1)
• Ability to walk independently (without use of wheelchair) for 30 steps. Use of a walker or cane is acceptable as long as the participant can walk for at least 30 steps.
• Aged \>18 years
• Ability to understand all study requirements and have a life expectancy greater than the study duration
• Vascular assessment (i.e., ABI, segmental pressure) that demonstrates the participant has adequate lower extremity perfusion
• Subject is willing and able to maintain the required offloading (as applicable for the location of the healed ulcer)
• Subject is willing and able to wear the Orpyx Sensory Insoles during ambulatory activity and at home during waking hours, and for a minimum of 5 hours per day
• Compatibility of the device with the participant's footwear
• Most recent HbA1c level of \< 12.0% (in the last 12 months)
• Amputations, if present, are compatible with the use of insoles

You may not qualify if:

• Active ulcer or presence of other open chronic wound (on foot or other body surface), regardless of etiology (e.g., vasculitis, neoplasms, or hematological disorders)
• History of known non-neuropathic foot ulcer (e.g., arterial, or venous insufficiency ulcer)
• Dementia
• Psychiatric illness or social situations that would limit compliance with the study
• Serious underlying balance dysfunction, regardless of etiology
• Significant cardiopulmonary or other systemic disease limiting the participant's ability to walk at least 30 steps or to stand for an amount of time equal to or greater than five (5) minutes
• Current participation in another clinical investigation of a medical device or a drug; or participation in such a study within 30 days prior to study enrolment
• Osteomyelitis or gangrene of the lower extremity
• Uncorrected plantar Charcot neuroarthropathy
• Bunion which would predispose ulcer formation (clinician discretion)
• Extreme equinus
• Hallux valgus
• Hallux rigidus / limitus
• HbA1c levels \>= 12%
• Any condition that would affect or limit the ability to properly fit both shoes with the device under study

Sponsors & Collaborators

• Orpyx Medical Technologies Inc.: lead

MeSH Terms

Conditions

Diabetes Mellitus; Peripheral Nervous System Diseases; Diabetic Foot

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Neuromuscular Diseases; Nervous System Diseases; Diabetic Angiopathies; Vascular Diseases; Cardiovascular Diseases; Foot Ulcer; Leg Ulcer; Skin Ulcer; Skin Diseases; Skin and Connective Tissue Diseases; Diabetes Complications; Diabetic Neuropathies

Central Study Contacts

Emily Bray

CONTACT

emily.bray@orpyx.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 11, 2023
• First Posted: July 18, 2023
• Study Start: April 1, 2025
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): January 1, 2028
• Last Updated: November 12, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share